Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]
Awaiting development
Reference number: GID-TA11065
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been scheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2027 when we will write to you about how you can get involved.